Related Experiment Video
Updated: Jun 29, 2025

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
Functional genetics reveals modulators of anti-microtubule drug sensitivity
Kuan-Chung Su1,2, Elena Radul1,2,3, Nolan K Maier1,4,2,5
1Whitehead Institute for Biomedical Research, 455 Main Street, Cambridge, MA 02142.
Abstract:
Microtubules play essential roles in diverse cellular processes and are important pharmacological targets for treating human disease. Here, we sought to identify cellular factors that modulate the sensitivity of cells to anti-microtubule drugs. We conducted a genome-wide CRISPR/Cas9-based functional genetics screen in human cells treated with the microtubule-destabilizing drug nocodazole or the microtubule-stabilizing drug taxol. We further conducted a focused secondary screen to test drug sensitivity for ~1400 gene targets across two distinct human cell lines and to additionally test sensitivity to the Kif11-inhibitor, STLC. These screens defined gene targets whose loss enhances or suppresses sensitivity to anti-microtubule drugs. In addition to gene targets whose loss sensitized cells to multiple compounds, we observed cases of differential sensitivity to specific compounds and differing requirements between cell lines. Our downstream molecular analysis further revealed additional roles for established microtubule-associated proteins and identified new players in microtubule function.
Insights
Researchers identified genes affecting cell sensitivity to microtubule drugs using CRISPR screens. This work reveals new drug targets and mechanisms for cancer therapy.
Area of Science:
- Cell Biology
- Genetics
- Pharmacology
Background:
- Microtubules are crucial for cell functions and are key targets for cancer drugs.
- Understanding cellular factors influencing drug response is vital for effective cancer treatment.
Approach:
- A genome-wide CRISPR/Cas9 screen identified genes modulating sensitivity to microtubule-targeting drugs (nocodazole, taxol).
- A secondary screen tested ~1400 gene targets across two cell lines for sensitivity to nocodazole, taxol, and the Kif11 inhibitor STLC.
Key Points:
- The screens identified gene targets that either increase or decrease sensitivity to anti-microtubule drugs.
- Observed differential drug sensitivity based on specific compounds and cell line variations.
- Downstream analysis uncovered new roles for known microtubule-associated proteins and identified novel players in microtubule dynamics.
Conclusions:
- This study provides a comprehensive map of genetic modifiers of anti-microtubule drug sensitivity.
- Identified novel therapeutic targets and elucidated mechanisms underlying drug response in cancer cells.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Destabilization of Microtubules
Treatment Resistant Cancers
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...